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doi:10.1016/j.jtcvs.2008.02.0341120 The Journal of Thoracic and CarObjective: Our objective was to review the long-term outcomes of patients with
Ebstein anomaly who underwent cardiac surgery at our institution.
Methods: Patient records were reviewed, and all patients were mailed a medical ques-
tionnaire or contacted by means of telephone. Patients who had pulmonary atresia
with an intact ventricular septum, complex conotruncal abnormalities, and atrioven-
tricular discordance with ventriculoarterial discordance were excluded.
Results: From April 1, 1972, to January 1, 2006, 539 patients with Ebstein anomaly
had 604 cardiac operations. The mean age at the time of the initial operation at our
institution was 24 years (range, 8 days–79 years). Three hundred seventeen of the pa-
tients were female. One hundred forty-three (26.5%) patients had a prior invasive car-
diac procedure before coming to Mayo Clinic. At the time of the first operation at
Mayo Clinic, 182 patients had tricuspid valve repair, and 337 had tricuspid valve re-
placement. The 30-day mortality was 5.9% for the entire cohort (2.7% after 2001).
Late survival was 84.7% at 10 years and 71.2% at 20 years. In a multivariate analysis
of overall mortality for the patients’ first operation at Mayo Clinic, increased hemat-
ocrit values, pulmonary valve stenosis, tricuspid valve replacement, absence of abla-
tion of an accessory pathway, miscellaneous arrhythmia procedure, branch pulmonary
artery enlargement, need for mechanical support postoperatively, emergency chest
opening in the intensive care unit, and absence of sinus rhythm at dismissal were
all predictive of mortality. When only preoperative characteristics were included, in-
creased hematocrit values, mitral valve regurgitation requiring surgical intervention,
prior cardiac procedure, and moderate-to-severe to severe reduction in right ventric-
ular systolic function were associated with mortality. Preoperative sinus rhythm and
an accessory pathway were associated with survival. Patients rated their health as ex-
cellent or good (New York Heart Association class I or II) in 83% of surveys returned.
Conclusion: Ebstein anomaly can be surgically treated with low perioperative mortal-
ity. Both tricuspid valve repair and tricuspid valve replacement are associated with
good long-term survival. Risk factors for poorer outcome included right, and/or left
ventricular systolic dysfunction; increased hemoglobin/hematocrit values; male sex;
right ventricular outflow tract obstruction; or hypoplastic pulmonary arteries.
E
bstein anomaly is a spectrum of tricuspid valve (TV) and right ventricular
(RV) dysplasia.1 The TV usually is insufficient but also might be stenotic.
Atrial septal defect (ASD) or patent foramen ovale (PFO) occurs in 30% todiovascular Surgery c May 2008
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DAbbreviations and Acronyms
ASD 5 atrial septal defect
ICU 5 intensive care unit
LV 5 left ventricular
MV 5 mitral valve
PFO 5 patent foramen ovale
RV 5 right ventricular
RVOT 5 right ventricular outflow tract
TR 5 tricuspid regurgitation
TV 5 tricuspid valve
TVrpl 5 tricuspid valve replacement
TVrpr 5 tricuspid valve repair
70% of cases, and ventricular pre-excitation is associated
with approximately 15% of cases. Less commonly, left ven-
tricular (LV) dysfunction and ventricular septal defect are ob-
served. Morbidity and mortality are thought to be related to
the degree of TV regurgitation or stenosis; the size, thickness,
and function of the right ventricle; and the presence or ab-
sence of an ASD. Patients with mild forms of Ebstein anom-
aly can be symptom free throughout their entire lives, but
patients with severe forms can die in utero.
The purpose of this report is to assess the long-term out-
come of operations for Ebstein anomaly. Specifically, we in-
tend to define operative and long-term mortality and the
determinants of operative and long-term mortality, to define
the determinants of reoperation, and to compare the outcomes
of TV repair (TVrpr) and TV replacement (TVrpl).
Materials and Methods
Patients
From April 1, 1972, to January 1, 2006, 539 patients with Ebstein
anomaly had an operation at the Mayo Clinic performed by one of
2 surgeons (GKD, JAD). Excluded from this cohort are patients
with pulmonary atresia with intact ventricular septum, complex con-
otruncal abnormalities, and atrioventricular discordance with ventri-
culoarterial discordance (‘‘corrected transposition’’).
Indications for Operation
The indications for operation included 1 or more of the following:
symptoms of dyspnea or right-sided heart failure (New York Heart
Association class III or IV), progressive exercise intolerance, tachy-
arrhythmias not controllable with medication or amenable to cathe-
ter-based intervention, and significant associated lesions, including
ASDs, ventricular septal defects, or pulmonary stenosis. In some
patients, progressive cardiomegaly, a cardiothoracic ratio of greater
than 0.65, severe cyanosis, and reduced LV function were an indi-
cation for operation.
Operative Management
Operative management of patients with Ebstein anomaly has been
described previously and consisted of (1) electrophysiologic map-
ping for localization of accessory conduction pathways in patients
with ventricular pre-excitation; (2) closure of any ASD or PFO;
(3) elimination of previously placed shunts and correction of any as-The Journal of Thoracsociated anomalies, such as ventricular septal defect, pulmonary ste-
nosis, or patent ductus arteriosus; (4) performance of any indicated
antiarrhythmia procedures, such as surgical division of accessory
conduction pathways, cryoablation of atrioventricular nodal re-entry
tachycardia, or the right-sided maze procedure; (5) consideration of
plication of the atrialized right ventricle; (6) reconstruction of the
TV when feasible or valve replacement; and (7) excision of redun-
dant right atrial wall (right reduction atrioplasty).1,2 In a few patients
a bidirectional cavopulmonary shunt was performed when the right
ventricle was markedly dilated and functioning poorly.3
Our initial repair, reported in 1979, consisted of plication of the
free wall of the atrialized portion of the right ventricle, posterior
tricuspid annuloplasty, and right reduction atrioplasty.4 The repair
was based on the construction of a monocusp valve by using the an-
terior leaflet; it brought the functional tricuspid annulus up to the
true tricuspid annulus. More recently, we have incorporated various
modifications of TVrpr based on the numerous variants of Ebstein
anomaly subsequently encountered.1 This includes TVrpr at the
level of the functional tricuspid annulus by bringing the anterior
papillary muscle or muscles toward the ventricular septum to facil-
itate coaptation of the leading edge of the anterior leaflet with the
ventricular septum, adding an anterior annuloplasty when indicated,
and selective plication or resection of the atrialized RV. In this
experience the 2 most important features that enabled a successful
durable repair were a free leading edge of the anterior leaflet and
at least 50% delamination of the anterior leaflet. TVrpr is performed
during aortic crossclamping, and therefore the valve anatomy could
be accurately assessed and repair sutures could be placed with min-
imal motion trauma. After completion of a valve repair, the TV is
tested by means of bulb syringe injection of saline into the right ven-
tricle with temporary pulmonary artery occlusion. Before 1982, in-
traoperative assessment to detect residual tricuspid regurgitation
(TR) after valve repair was performed by introducing an exploring
finger into the right atrium through the appendage for direct palpa-
tion of the TV in the beating heart. Intraoperative assessment of the
TV after repair or replacement was performed with epicardial echo-
cardiography from 1982 through 1985, after which transesophageal
echocardiography was used routinely.
When the TV could not be reconstructed, the valve tissue adja-
cent to the RV outflow tract was excised, and a prosthetic valve
(bioprosthetic more often than mechanical) was inserted.5 The suture
line was deviated cephalad to the atrioventricular node, bundle of
His, and membranous septum to avoid injury to the conduction sys-
tem. The suture line was deviated cephalad to the tricuspid annulus
posterolaterally, where the tissues were frequently very thin, to avoid
injury to the right coronary artery. The struts of the bioprosthetic
valve were oriented so that they straddled the membranous septum
and conduction tissue. The valve sutures were tied while the heart
was perfused and beating to detect any rhythm abnormalities.
At the beginning of our experience, a portion of the atrialized
right ventricle was routinely excised. However, postoperative ven-
tricular arrhythmias were common, and we believed this could be re-
lated to ventricular suture lines, compromise of small branches of
the right coronary artery, or both. In addition, we have a new appre-
ciation that in some patients, the thin-walled atrialized right ventricle
maintains contractility. Our current practice is to plicate or resect an
atrialized ventricle selectively. This is most often performed when it
is thin, transparent, and dyskinetic on echocardiography.ic and Cardiovascular Surgery c Volume 135, Number 5 1121
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Two of the investigators (MLB and DJD) collected all pertinent data
from the Mayo Clinic medical record. This included all follow-up in-
formation regarding reoperation and deaths that had been received
from non–Mayo Clinic–referring physicians and health care providers.
In addition to review of medical records, vital status was assessed
through an online database (www.Accurint.com). Detailed health
status questionnaires were mailed to all participants not known to
be dead. Patients who did not return or complete the questionnaire
were sent a second questionnaire. If the second questionnaire was
not returned or completed, attempts were made to contact the patient
by means of telephone. Two hundred eighty-five patients (64% of
448 alive patients) completed questionnaires and Health Insurance
Portability and Accountability Act forms. Forty-three patients com-
pleted a questionnaire but did not complete the Health Insurance
Portability and Accountability Act form, and 28 patients refused
to complete the survey.
Statistical Analysis
Statistical analysis included the Fisher exact test and the c2 test of as-
sociation for comparing proportions. Logistic regression was carried
out to analyze early (#30 days) mortality. Log-rank tests and Cox
proportional hazards models were used to identify univariate and
multivariate predictors of overall mortality, late (.30 days) mortality,
and late (.30 days) reoperation. In addition, late survival free from
reoperation was determined by using death or reoperation as an event.
Kaplan–Meier survival curves were drawn for all late outcomes. Pre-
dictor variables were analyzed as continuous or categorical variables,
as appropriate. Continuous variables were dichotomized when either
statistically or clinically appropriate. Multivariate model building
was based on a stepwise selection method. The SAS 9.1.3 statistical
software system (SAS, Institute Inc, Cary, NC) was used throughout.
Only 2-tailed probability values are reported.
Independent variables included, among others: age at operation;
year of operation; surgeon; patient sex; age at diagnosis; cardiotho-
racic ratio on chest radiographic analysis; presence and type of pre-
operative arrhythmia; rhythm on electrocardiographic analysis;
blood oxygen saturation (oximetry); hemoglobin value; hematocrit
value; and previous cardiac procedures (see the complete list and
definitions shown in Appendix E1). Associated cardiac defects
and type of operation (including TVrpr, TVrpl, and miscellaneous
concomitant procedures) also were included. Echocardiographic
variables included preoperative and postoperative RV size and func-
tion; degree of tricuspid stenosis, regurgitation, or both; degree of
pulmonary stenosis or regurgitation; degree of mitral valve (MV)
stenosis or regurgitation; and LV ejection fraction. The degree of
TR, RV or LV systolic dysfunction, and RV enlargement was
graded as none, mild, moderate, moderate-to-severe, and severe
on transthoracic echocardiographic analysis. Echocardiographic
variables with more than 15% missing data (and up to 45%) were
not included in the stepwise selection for the initial multivariate
model. To assess their effects, a second multivariate model was fit
by first forcing all the variables chosen for the initial multivariate
model and then putting in the variables with missing data one by
one to see whether they are significant after adjusting for the effects
from the initial multivariate model.
The initial operation at Mayo Clinic was TVrpr for 182 patients,
TVrpl for 337 patients, and a variety of nonvalve operations for 20
patients (Figure 1). Of the patients who initially had TVrpr at the1122 The Journal of Thoracic and Cardiovascular Surgery c MMayo Clinic, 1 patient subsequently underwent rerepair, and 35 sub-
sequently had TVrpl (Figure 1). In both the univariate and
multivariate analyses, the 35 patients who had both TVrpr and
TVrpl were included both in the repair group and in the replacement
group. Also, 6 patients who had ‘‘other’’ operations and subsequent
TVrpl were included in the replacement group. Thus the TVrpr
group had 182 patients, and the TVrpl group had 378 patients.
Results
Patient Characteristics at Initial Operation at Mayo
Clinic
The mean patient age was 24.16 18.1 years (range, 8 days–
79 years), with 317 (58.8%) patients being female (Table
E1). There was only 1 newborn in this cohort (#30 days at
the time of the operation) and 12 patients under the age of
1 year at time of the first operation at Mayo Clinic. Opera-
tions took place between April 1, 1972, and January 1,
2006. Most patients had associated cardiac anomalies (Tables
E2 and E3). The most common was an ASD, which was pres-
ent in 452 (83.9%) of the patients. An accessory conduction
pathway was demonstrated by means of electrophysiologic
testing in 74 (13.7%) patients, and a history of pre-excitation
was obtained from 91 (16.9%) patients.
One hundred forty-three patients had prior cardiac proce-
dures before coming to the Mayo Clinic (Table 1). The 4
most common procedures were closure of an ASD or PFO
in 41 (7.6%) patients, surgical ablation of an accessory path-
way in 35 (6.5%) patients, placement of a systemic to pulmo-
nary artery shunt in 33 (6.1%) patients, and TVrpr or TVrpl in
18 (3.3%) patients. Rereplacement of a tricuspid prosthesis
was done for significant prosthesis regurgitation, stenosis,
or both. None were replaced for patient–prosthesis mismatch.
Initial Operations at Mayo Clinic
The initial operation at Mayo Clinic was TVrpl for 337
(62.5%) patients and TVrpr for 182 (33.8%; Table 2) pa-
tients. An ASD or PFO was closed in 450 (83.5%) patients.
6 TVrpl 1 TVrpr 35 TVrpl 19 TVrpl
337 TVrpl
1st Operation At Mayo
20 ‘Other’ 182 TVrpr
3 TVrpl
TVrpr = TV repair
TVrpl = TV Replacement
Does not include ‘other’ operations (shunts,





Figure 1. Operations on the tricuspid valve (TV) at Mayo Clinic.ay 2008
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DOverall Morbidity
The most common early complication after the first operation
at Mayo Clinic (excluding patients who died #30 days
postoperatively) was an atrial arrhythmia (atrial fibrillation,
flutter, supraventricular tachycardia, or premature atrial con-
tractions), which occurred in 15% of patients (Table E4).
Low cardiac output occurred in 5.7%, respiratory insuffi-
ciency occurred in 5.5%, and transient third-degree atrioven-
tricular block occurred in 4.5%. Eleven (2.2%) patients had
permanent atrioventricular block.
The most common reason for early reoperation (#30 days
after the index operation) was for bleeding (16 patients) and
delayed sternal closure (16 patients; Table E5). Eleven
patients required emergency reopening of the chest in the in-
tensive care unit (ICU). Permanent pacemakers were inserted
in 21 patients: 12 for third-degree atrioventricular block and
9 for miscellaneous reasons.
Entire Cohort
Overall total mortality. Data from all 539 patients were
used in this analysis. The 30-day and 1-, 5-, 10-, 15-, and
20-year survivals were 94%, 92%, 88%, 85%, 81%, and
71%, respectively (Figure 2 and Table 3). In a multivariate
model pulmonary valve stenosis, a higher hematocrit value,
TVrpl, branch pulmonary artery enlargement, emergency
opening of the chest in the ICU, a miscellaneous arrhythmia
procedure (cryoablation, left-sided maze procedure, or liga-
tion of the left atrial appendage), and postoperative need
for mechanical cardiac support were associated with higher
mortality. Ablation of an accessory pathway and sinus
rhythm at discharge were associated with lower mortality.
When only preoperative variables were included in the
model, a higher hematocrit value, MV regurgitation requiring
TABLE 1. Previous cardiovascular procedures performed
elsewhere
Patients
Total, n 5 539 %
Any prior cardiovascular procedure 143 26.5
Closure of ASD or PFO 41 7.6
Ablation of accessory pathway,
catheter or surgical
35 6.5
Systemic-to-pulmonary artery shunt 33 6.1
Miscellaneous prior procedures 29 5.4
Tricuspid valve repair or replacement 18 3.3
Cavopulmonary shunt 12 2.2
Closure of ventricular septal defect 7 1.3
Pulmonary valvotomy 7 1.3
Coronary stenting or CABG 5 0.9
Repair of coarctation 5 0.9
Closure of patent ductus arteriosus 5 0.9
Others 6 1.1
ASD, Atrial septal defect; PFO, patent foramen ovale; CABG, coronary artery
bypass grafting.The Journal of Thoracsurgical repair, and moderate-to-severe and severe RV sys-
tolic dysfunction were associated with higher mortality, and
an accessory pathway was associated with lower mortality.
There were numerous variables associated with mortality
in a univariate fashion (Table 3). Those of particular interest
included increased preoperative RV size and decreased
RV systolic function, preoperative decreased LV systolic
TABLE 2. Surgical procedures at the time of the first Mayo
Clinic operation
Patients
Total, n 5 539 %
Closure of ASD or PFO 450 83.5
Right reduction atrioplasty 400 74.2
Tricuspid valve replacement 337 62.5
Anterior right pericardiectomy 270 50.1
Plication of atrialized right ventricle 186 34.5
Tricuspid valve repair 182 33.8
Intraoperative ablation of accessory pathway(s) 63 11.6
Right-sided maze procedure 52 9.7
Repair of pulmonary stenosis 33 6.1
Closure of systemic-to-pulmonary artery shunt 26 4.8
Closure of ventricular septal defect 23 4.3
Miscellaneous arrhythmia surgery 19 3.5
RVOT enlargement 15 2.8
Creation of shunt 12 1.7
Ablation of AV nodal re-entrant tachycardia 10 1.9
Mitral valve replacement or repair 10 1.9
Coronary artery bypass grafting 10 1.9
Repair partial atrioventricular septal defect 8 1.5
Branch pulmonary artery enlargement 6 1.1
Pulmonary valve replacement 5 0.9
Closure of patent ductus arteriosus 5 0.9
Fontan with tricuspid valve excision 4 0.7
Mechanical assist device or transplantation 4 0.7
ASD, Atrial septal defect; PFO, patent foramen ovale; RVOT, right ventricular
outflow tract; AV, atrioventricular.
Figure 2. Long-term survival for all 539 patients. Time 0 is the time
of the first cardiac operation at the Mayo Clinic.ic and Cardiovascular Surgery c Volume 135, Number 5 1123
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DTABLE 3. Univariate and multivariate predictors of early mortality (<30 days), late mortality (>30 days), and survival free
from late reoperation (>30 days) for all patients at the initial operation at the Mayo Clinic





















Male .019 .031 1.48 .038
Younger age at operation (,12 y) .002 3.23 ,.001
Younger age at diagnosis (Y 10 y) .001
Preoperative CT ratio .0.65 .033 .019
Preoperative O2 saturation #85%* .035
Preoperative hemoglobin .15 g/dL .016 .016
Preoperative hematocrit ([ 10%) .016 .020 1.53 .014
Echocardiography*
Moderate-severe to severely enlarged
preoperative RV size
.025
Moderate-severe to severely reduced
preoperative RV function
.029 2.895 .002
Moderate to severely reduced
preoperative LV function
.056 ,.001 .004 2.31 .019
Moderate-severe to severely enlarged
postoperative RV size
.002 .018
Moderate-severe to severely reduced
postoperative RV function
.001 .001 .004 2.44 .001
Moderate to severely reduced
postoperative LV function
,.001 .010 3.67 ,.001 .025
PV stenosis, mild or greater ,.001 2.00 .045
Pulmonary artery stenosis/hypoplasia ,.001
Associated heart disease
Accessory conduction pathway .021 0.28 .034
Coronary artery disease
MV regurgitation requiring surgical intervention ,.001 8.17 .006 ,.001
Pulmonary artery stenosis or hypoplasia .034
Severe PV regurgitation ,.001
Surgical procedures
No TV repair .029 .004
TV replacement .008 .009
No ablation of accessory pathway(s) .017 0.21 .033
Repair PV stenosis .043 .040
CABG
Permanent pacing wires .019
Miscellaneous arrhythmia procedure .005 .002 3.75 .008
MV replacement or repair .019 .025
RVOT enlargement .003 4.90 .001 .007
Branch PA enlargement .037 4.40 .041
Pulmonary valve replacement .008
LVAD/transplantation/IABP .020
Prior cardiac procedures
Any prior procedure .048 .036
Prior pulmonary valvotomy .020
Prior systemic-to-pulmonary shunt .039
Prior cavopulmonary shunt ,.001 3.07 .006
Early nonfatal complication
Atrial arrhythmias .002 .026
Wide complex tachycardia .002 .029 2.45 .007
Respiratory insufficiency .042 ,.001
1124 The Journal of Thoracic and Cardiovascular Surgery c May 2008
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Renal insufficiency ,.001 6.79 ,.001
Dialysis .006
Low cardiac output .001
Thrombus in RA or TV .032
Deep sternal infection .022 11.78 ,.001
Intra-aortic balloon pump .007
Early reoperation
Tamponade ,.001 15.99 ,.001 .044
LVAD, RVAD, or mechanical support ,.001 82.54 ,.001 ,.001 ,.001
Creation of shunt .004 ,.001
Closure of shunt .026
Emergency opening of chest in ICU ,.001 31.33 ,.001 ,.001
Miscellaneous early reoperation ,.001 .002 .009
Preoperative arrhythmia and laboratory data
Past history of any arrhythmia .013
No accessory pathway .027
Patients in sinus rhythm on preoperative ECG .003 0.41 .020
Increased QRS duration .001 1.15 .001
uni, Univariate; OR, Odds ratio;mv, multivariate; CT, cardiothoracic; RV, right ventricular; LV, left ventricular; PV, pulmonary valve;MV, mitral valve; TV, tricuspid
valve; CABG, coronary artery bypass grafting; RVOT, right ventricular outflow tract; PA, pulmonary artery; LVAD, left ventricular assist device; IABP, intra-
aortic balloon pump; RVAD, right ventricular assist device; ICU, intensive care unit; ECG, electrocardiography. *Missing data (.15% and ,45%).CH
Dfunction, cardiothoracic ratio of greater than 65% determined
by means of chest radiography, and number of variables re-
lated to a right ventricular outflow tract (RVOT) obstruction
or small pulmonary arteries.
Overall early mortality. There were 33 deaths 30 days or
less after the operation. In a multivariate model emergency
opening of the chest in the ICU, postoperative need for
mechanical cardiac support, and early tamponade were asso-
ciated with higher mortality. When only preoperative vari-
ables were entered into the model, moderate-to-severe and
severe RV systolic dysfunction were the only variables asso-
ciated with higher mortality (Table 3).
Overall late mortality. When the 33 early deaths were
excluded, the 1-, 5-, 10-, 15-, and 20-year survivals were
98%, 94%, 90%, 86%, and 76%, respectively. In a multivar-
iate model MV regurgitation requiring operative repair, RV
outflow tract enlargement, enlargement of the pulmonary ar-
teries, renal insufficiency, and increased QRS duration were
associated with increased mortality. Late survival was associ-
ated with ablation of an accessory pathway and preoperative
sinus rhythm (Table 3).
When only preoperative variables were entered into the
model, MV regurgitation requiring operation, increased he-
matocrit values, and LV dysfunction were associated with
greater mortality and an accessory conduction pathway and
the presence of preoperative sinus rhythm were associated
with lower mortality.The Journal of ThoraOverall freedom from late reoperation. The 1-, 5-, 10-,
15-, and 20-year freedoms from any (on the TV or other)
reoperation were 97%, 91%, 82%, and 70%, respectively.
In a multivariate model hypoplastic or stenotic pulmonary ar-
teries, insertion of an intra-aortic balloon pump postopera-
tively, prior cavopulmonary shunt, younger age at the time
of the operation, and earlier era of operation were associated
with late reoperation. When only preoperative variables were
entered into the model, pulmonary valve stenosis, hypoplas-
tic or stenotic pulmonary arteries, prior cavopulmonary
Figure 3. Survival free from late reoperation (on the tricuspid
valve or other) for all patients after the first cardiac operation at
the Mayo Clinic.cic and Cardiovascular Surgery c Volume 135, Number 5 1125
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Dshunt, younger age at the time of the operation, and an earlier
era of operation were associated with late reoperation.
Survival free from late operation. The 1-, 5-, 10-, 15-,
and 20-year survivals and freedoms from any (on the TV or
other) reoperation were 95%, 86%, 74%, 62%, and 46%, re-
spectively (Figure 3). In a multivariate model the following
variables were associated with an increased risk of death or
reoperation: deep sternal wound infection, miscellaneous
arrhythmia procedure, wide complex tachycardia, moderate-
to-severe or severe postoperative RV systolic dysfunction,
moderate-to-severe preoperative LV systolic dysfunction,
and age less than 12 years at the time of the operation.
When only preoperative variables are considered, a prior cav-
opulmonary shunt, pulmonary valve stenosis, male sex, mod-
erate-to-severe preoperative LV systolic dysfunction, and age
less than 12 years were associated with higher risk of death or
late reoperation (Table 3).
Recurring variables. Several variables were statistically
significant in a univariate model for 3 of the 4 following
subsets: overall mortality, early mortality, late mortality,
and survival free from late reoperation (Table 3). The vari-
ables were male sex, greater preoperative cardiothoracic ra-
tio, higher preoperative hemoglobin or hematocrit values,
reduced preoperative RV and LV systolic function, enlarged
postoperative RV size, MV regurgitation requiring surgical
intervention, no TVrpr, TVrpl, repair of pulmonary valve ste-
nosis, miscellaneous arrhythmia procedure, RVOT enlarge-
ment, and need for mechanical support.
TVrpr Versus TVrpl
The patients whose operations at the Mayo Clinic were
TVrprs differed from those whose operations were TVrpls
in a number of ways. In these comparisons, patients who
had TVrpr followed by TVrpl were only included in the
TVrpr group. In general, patients who had valve repair
were operated on earlier in the series (mean year of
operation, 1989 vs 1996). On preoperative transthoracic
echocardiographic analysis, the TV was judged to be not
repairable in 32% of the repair group and in 85% in the re-
placement group. On echocardiographic analysis, anatomic
severity of the valve malformation was accessed to be mod-
erately severe and severe in 61% of the repair group and 93%
of the replacement group. The replacement group had more
prior cardiac procedures than the repair group. All of these
differences were statistically significant (Table 4). Postoper-
atively, 13% of the patients who had valve repair had at least
moderate residual TR, whereas no patients who had
replacement had moderate residual TR.
TVrpr Subset
Overall mortality. Data from 182 patients who had TVrpr
were used in this analysis. The 30-day and 1-, 5-, 10-, 15-,
and 20-year survivals were 95%, 93%, 93%, 88%, 87%,
and 76%, respectively. In a multivariate model higher preop-1126 The Journal of Thoracic and Cardiovascular Surgery c Merative hematocrit values and previous cardiac operations
were associated with higher mortality. Preoperative sinus
rhythm was associated with lower mortality. There were nu-
merous variables associated with mortality in a univariate
fashion (Table 5). Those of particular interest included preop-
erative decreased RV or LV systolic function, lower preoper-
ative blood oxygen saturation, and higher hemoglobin levels.
Early mortality. There were 9 deaths at 30 days or sooner
after the operation. There were too few deaths to develop
a multivariate model. In a univariate model reduced preoper-
ative RV and LV systolic function, the need for permanent
pacing wires postoperatively, and the need for a ventricular
assist device postoperatively were associated with mortality
(Table 5).
Late mortality. When the 9 early deaths were excluded,
the 1-, 5-, 10-, 15-, and 20-year survivals were 98%, 98%,
TABLE 4. Differences between the TVrpr and TVrpl patient
groups




TV repairable on echocardiography, yes 46.67 7.08 ,.001
TV repairable on echocardiography,
equivocal
21.33 7.50
Pulmonary artery architecture, hypoplastic 1.65 6.12 .040
Pulmonary artery architecture, discrete
stenosis
0.55 1.46
Postoperative RV function (grade 3 or 41) 15.71 48.73 ,.001
Postoperative TV regurgitation
(grade 3 or 41)
12.71 0.00 ,.001
Any prior cardiac procedure 13.74 34.11 ,.001
Prior closure of atrial septal defect 1.65 11.37 ,.001
Prior TVrpr 0.00 3.79 .008
Prior systemic-to-pulmonary artery shunt 2.75 7.00 .043
Prior ablation of accessory pathway 2.75 8.75 .009
Right reduction atrioplasty 86.81 76.97 .007
Plication of atrialized right ventricle 69.78 18.95 ,.001
Right-sided maze procedure 3.85 13.12 .001
Perioperative atrial arrhythmia, atrial
fibrillation, atrial flutter, PACs, SVT
8.24 17.20 .005
Perioperative low cardiac output state 2.20 7.00 .020
Respiratory insufficiency 2.20 6.71 .036






Secondary sternal closure 0.00 4.37 .002




Patients in sinus rhythm preoperatively 96.70 91.84 .031
TVrpr, Tricuspid valve repair; TVrpl, tricuspid valve replacement; TV, tricus-
pid valve; RV, right ventricular; PACs, premature atrial contractions; SVT,
supraventricular tachycardia; HB, heart block; EP, electrophysiologic.ay 2008
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DTABLE 5. Variables significant in a univariate model and multivariate model for tricuspid valve repair
Early mortalityy Late mortality >30 d Survival free from late reoperation
P value, uni P value, uni HR, mv P value, mv P value, uni HR, mv P value, mv
Demographic
Male sex .043 .050 1.83 .043
Preoperative hematocrit .45% .049
Echocardiography*
Moderate-severe or severely reduced preoperative
RV function
.035
Moderate to severe reduction in preoperative
LV function
.034 .007 .014
Moderate to severe MV regurgitation ,.001
Mild or greater pulmonary valve stenosis ,.001 5.14 .005
Pulmonary artery stenosis or hypoplasia .008
Moderate-severe to severely reduced postoperative
RV function
.016
Moderate to severe reduction in postoperative
LV function
,.001 .005 7.61 .010
Associated heart disease
Coronary artery disease .001 .022
Subvalvular pulmonary stenosis/RVOT obstruction .028
Miscellaneous associated cardiac defects .010
Previous CV procedure
Any prior cardiac procedure ,.001 5.97 ,.001 .003 2.33 .020
Prior cavopulmonary shunt .007 ,.001
Prior closure of ventricular septal defect .022
Prior coronary stenting or CABG .001 .002
Concomitant procedures
Right-sided maze procedure .003 6.12 .021
CABG .001
Permanent pacing wires .002
Early, nonfatal complications
Low cardiac output state ,.001
Early reoperation
Emergency opening of the chest in ICU .012
Preoperative arrhythmia
Cardiac arrest before surgical intervention .029 .001
Patients in sinus rhythm preoperatively ,.001 0.08 ,.001
uni, Univariate; HR, hazard ratio; mv, multivariate; RV, right ventricular; LV, left ventricular; MV, mitral valve; RVOT, right ventricular outflow tract; CV, cardio-
vascular; CABG, coronary artery bypass grafting; ICU, intensive care unit. *Missing values (.15% and,45%). yNomultivariate model because of low number
of events.93%, 92%, and 80%, respectively. In a multivariate model
the previous cardiac procedure was associated with increased
mortality, and preoperative sinus rhythm was associated with
lower mortality (Table 5).
Freedom from late reoperation. The 1-, 5-, 10-, 15-, and
20-year freedoms from reoperation on the TV were 100%,
95%, 89%, 77%, and 64%, respectively. In a multivariate
model prior surgical procedure and increased QRS duration
were associated with lower freedom from reoperation. Plica-
tion of an atrialized right ventricle reduced the need for late
reoperation. When only preoperative variables were entered
into the model, patients with a prior cardiac surgical proce-
dure were associated with a lower freedom from reoperation.The Journal of ThorThe freedom from reoperation rate over a 20-year period was
51%, 83%, and 61% for patients 10 years of age or less, 11 to
20 years of age, and more than 20 years of age, respectively
(P 5 .032).
Survival free from late reoperation. The 1-, 5-, 10-, 15-,
and 20-year survivals free from reoperation on the TV was
98%, 93%, 84%, 73%, and 56%, respectively. In a multivari-
ate model a greater risk of death or reoperation was associated
with the following variables: right-sided maze procedure,
pulmonary valve stenosis, a previous cardiovascular proce-
dure, greater QRS duration, moderate-to-severe LV systolic
dysfunction postoperatively, and male sex. When only preop-
erative variables were included, male sex, pulmonary valveacic and Cardiovascular Surgery c Volume 135, Number 5 1127
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Dstenosis, and previous cardiovascular procedures were asso-
ciated with greater risk of death or late reoperation (Table 5).
Recurring variables. Several variables were statistically
significant in a univariatemodel for 3 of the 4 following subsets:
overall mortality, early mortality, late mortality, and survival
free from late reoperation (Table 5). The 4 variables included
male sex, reduced preoperative and postoperative LV systolic
function, any prior cardiac procedure, prior cavopulmonary
shunt, and prior stenting or coronary artery bypass grafting pro-
cedure.
TVrpl Subset
Overall mortality. Data from 378 patients who had TVrpl
were used in this analysis. Of these 378 patients, 43 (11.4%)
had a prior TVrpr. The 30-day and 1-, 5-, 10-, 15-, and 20-year
survivals were 94%, 91%, 86%, 83%, 74%, and 68%, respec-
tively. In a multivariate model repair of pulmonary valve
stenosis, miscellaneous arrhythmia procedure, mechanical
circulatory support postoperatively, and emergency opening
of the chest in the ICU were associated with higher mortality.
Surgical ablation of an accessory pathway and postoperative
sinus rhythm were associated with lower mortality.
When only preoperative variables were included in the
model, MV regurgitation requiring an operation, and reduced
LV systolic function were associated with increased mortal-
ity. The presence of an accessory conduction pathway was
associated with lower mortality. There were numerous vari-
ables associated with higher mortality in a univariate fashion
(Table 6). Those of particular interest included increased
preoperative RV size and decreased RV systolic function,
preoperative decreased LV systolic function, radiographic
cardiothoracic ratio of greater than 0.65, lower blood oxygen
saturation, and higher hemoglobin levels.
Early mortality. There were 23 deaths at 30 days or less
after the operation. In a multivariate model emergency
opening of the chest in the ICU and postoperative need for
a ventricular assist device were associated with increased
mortality. When only preoperative variables were entered
into the model, moderate and severe LV systolic dysfunction
was the most significant variable associated with mortality,
and after adjusting for it, no other risk factors were significant
(Table 6).
Late mortality. When the 23 early deaths were excluded,
the 1-, 5-, 10-, 15-, and 20-year survivals were 97%, 92%,
88%, 79%, and 72%. In a multivariate model RVOT enlarge-
ment, wide complex tachycardia, early reoperation, and QRS
duration were associated with higher mortality. An accessory
pathway was associated with lower mortality (Table 6).
Considering only preoperative variables, MV regurgitation
requiring an operation and reduced RV systolic function
preoperatively were associated with late mortality. An acces-
sory pathway was associated with late survival.
Freedom from late reoperation on the TV. The 1-, 5-,
10-, 15-, and 20-year freedoms from reoperation were 99%,1128 The Journal of Thoracic and Cardiovascular Surgery c Ma95%, 83%, 70%, and 59%, respectively. In a multivariate
model younger age, greater MV regurgitation requiring
surgical intervention, postoperative need for an intra-aortic
balloon pump, and a catheter ablation procedure were associ-
ated with lower freedom from reoperation. When only preop-
erative variables were entered into the model, younger age at
the time of the operation, MV regurgitation requiring an
operation, a catheter ablation procedure, and a prior cardiac
procedure were associated with lower freedom from reoper-
ation.
Survival free from reoperation on the TV. The 1-, 5-,
10-, 15-, and 20-year freedoms from reoperation were 96%,
87%, 74%, 56%, and 44%, respectively. In a multivariate
model the following variables were associated with death
or late reoperation on the TV: MV regurgitation requiring
an operation, postoperative renal insufficiency, wide com-
plex tachycardia, moderate-to-severe preoperative reduction
of LV systolic function, and age less than 12 years at the
time of operation. Preoperative variables associated with
death or late reoperation on the TV were as follows: MV
regurgitation requiring an operation, moderate-to-severe pre-
operative reduction of LV systolic function, and younger age
at the time of the operation (Table 6).
Recurring variables. Several variables were statistically
significant in a univariate model for 3 of the 4 following sub-
sets and were associated with a lower rate of reoperation:
overall mortality, early mortality, late mortality, and survival
free from late reoperation (Table 6). They included increased
preoperative cardiothoracic ratio, reduced preoperative RV
and LV systolic function, reduced postoperative RV systolic
function, MV regurgitation requiring surgical intervention,
miscellaneous arrhythmia surgery, postoperative wide com-
plex tachycardia, postoperative mechanical support or mis-
cellaneous early operation.
A summary of all independent predictors of overall
mortality, early and late mortality, and survival free from
reoperation is shown in Table 7.
TVrpr and TVrpl in Patients Less Than 12 and 12 or
More Years of Age
Patients were divided into groups less than 12 and 12 or more
years of age (Figure 4) and stratified into patients who had
TVrpr or TVrpl to examine survival free from late reopera-
tion. This age cutoff was chosen because an adult-sized TV
prosthesis could usually be inserted in patients who were
12 years of age or older. Patients were analyzed in an in-
tent-to-treat manner in that patients who received a TVrpr
at the Mayo Clinic followed by a TVrpl were included in
the TVrpr group only for this analysis (n 5 35). There was
no difference between those who had TVrpr and TVrpl in
survival free from late reoperation for patients 12 years of
age and older. However, there was a significant advantage
for patients who received a TVrpr (P , .001) compared
with a TVrpl at less than 12 years of age. For patients lessy 2008
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DTABLE 6. Variables significant in a univariate and multivariate model for tricuspid valve replacement






















Younger age at operation ,12 y ,.001 0.33 ,.001
Age at diagnosis (Y 10 y) .008
[ Preoperative CT ratio .003 .01 .045
Preoperative decreased oxygen saturation* .011
Echocardiography*
Moderate-severe to severely enlarged preoperative RV size .019
Moderate-severe to severely decreased preoperative RV function .033 .003 .021
Moderate to severely reduced preoperative LV function .011 2.79 .009 .008 2.28 .005
Moderate-severe to severely enlarged postoperative RV size .018
Moderate-severe to severely reduced postoperative RV function .001 3.08 .028 .038
Moderate to severely reduced postoperative LV function .006
Associated heart disease
Accessory conduction pathway .013 0.11 .029
Mitral regurgitation requiring surgical intervention .006 ,.001 7.13 .001
Prior cardiac procedures
Any prior cardiac procedure .027
Prior closure of atrial septal defect .020
Concomitant procedures
Anterior right pericardiectomy .005
Ablation of accessory pathway(s)
Repair PV stenosis .011
Systemic-to-pulmonary artery shunt .015
Miscellaneous arrhythmia procedure .006 .041
Mitral valve replacement or repair .001 5.34 .025 .017
RVOT enlargement ,.001 8.09 ,.001
LVAD/transplantation/IABP .010
Early nonfatal complication
Ventricular arrhythmia, PVCs, ventricular tachycardia,
or ventricular fibrillation
.034
Wide complex tachycardia, ventricular tachycardia
or ventricular fibrillation
,.001 3.32 .002 .002 2.42 .007
Atrial arrhythmia, atrial fibrillation, atrial flutter, PACs, SVT .02 .029
Low cardiac output state .006
Thrombus in RA or on TV .023
Respiratory insufficiency .023 ,.001




LVAD, RVAD, or mechanical support ,.001 125.4 ,.001 ,.001 ,.001
Creation of shunt
Pericardiectomy
Emergency opening of chest in ICU ,.001 33.4 ,.001
Miscellaneous early reoperation .002 .034 9.79 .003 ,.001
Preoperative arrhythmia data
Any preoperative arrhythmia .027
Accessory pathway .01
Patients with pre-excitation on preoperative ECG .031
uni, Univariate;OR, odds ratio;mv, multivariate; HR, hazard ratio; CT, cardiothoracic; RV, right ventricular; LV, left ventricular; PV, pulmonary valve; RVOT, right ven-
tricular outflow tract; LVAD, left ventricular assist device; IABP, intra-aortic balloon pump; PACs, premature atrial contractions;SVT, supraventricular tachycardia;
RA, right atrium; TV, tricuspid valve; RVAD, right ventricular assist device; ICU, intensive care unit; ECG, electrocardiography. *Missing data (.15% and,45%).The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 5 1129
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DTABLE 7. Summary of hazard ratios of multivariate models
Overall mortality
All patients (n 5 539) TV repair (n 5 182) TV replacement (n 5 378)
All variables
LVAD, RVAD, or mechanical support 17.77 32.11
Emergency opening of chest in ICU 9.90 17.85
Enlargement of pulmonary arteries 4.97
Pulmonary stenosis: mild or greater 3.20
Miscellaneous arrhythmia procedure 3.18 3.84
Tricuspid valve replacement 1.92
HCT results (increase by 10 units) 1.75
Sinus, discharge rhythm by ECG 0.25 0.224 0.38
Ablation of accessory pathways 0.20 0.09
Repair of pulmonary stenosis 3.81
Sinus, preoperative rhythm by ECG 0.17
Preoperative variables only
Mitral regurgitation requiring surgical intervention 3.07 5.89
Preoperative RV function moderate-severe to severely reduced 2.76
HCT results (increase by 10 units) 1.46 1.61
Accessory pathway, associated cardiac defect 0.51 0.27
Preoperative LV function, moderate to severely reduced 2.75
Previous cardiovascular procedure 3.44
Sinus, preoperative rhythm by ECG 0.15
Early mortality
All patients TV repair TV replacement
All variables
LVAD, RVAD, or mechanical support 82.54 125.36
Emergency opening of chest in ICU 31.33 33.43
Tamponade 15.99
Preoperative variables only
Preoperative RV function, moderate-severe to severely reduced 2.90
Preoperative LV function, moderate to severely reduced 3.08
Late mortality
All patients TV repair TV replacement
All variables
Enlargement of RV outflow tract 4.90 8.09
Miscellaneous early reoperation 9.79
Branch PA enlargement 4.40
Prior cardiovascular procedure 5.97
Renal insufficiency, early postoperative complication 6.79 3.33
Wide complex tachycardia 3.32
MV regurgitation requiring operative treatment 8.17
QRS duration (increase by 10 units) 1.15 1.14
Sinus, preoperative rhythm by ECG 0.41 0.08
Accessory pathway on EP study 0.11
Ablation of accessory pathways 0.21
Preoperative variables only
Mitral regurgitation requiring surgical intervention 9.86 5.51
Prior cardiovascular procedure 5.97
Preoperative RV function: moderate-severe to severely reduced 2.79
Sinus, preoperative rhythm by ECG 0.42 0.08
Accessory pathway 0.28 0.28
Increased HCT (10 units) 1.53
Preoperative LV function, moderate to severely reduced 2.27 2.791130 The Journal of Thoracic and Cardiovascular Surgery c May 2008
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Survival free from late reoperation
All patients TV repair TV replacement
All variables
Male sex 1.29
Age ,12 y 3.23 0.33
Preoperative LV function: moderate to severely reduced 2.31 2.28
Postoperative LV function: moderate to severely reduced 7.61
Pulmonary stenosis: mild or greater 2.36
Postoperative RV function: moderate severe to severely reduced 2.44
Previous cardiovascular procedures 2.14
Mitral valve regurgitation requiring surgical intervention 7.13
Right-sided maze procedure 8.05
Miscellaneous arrhythmia procedure 3.75
Wide complex tachycardia 2.45 2.42
Deep sternal wound infection 11.78
Renal insufficiency 3.96
Prior cavopulmonary shunt
Increased QRS duration ([ 10 S) 1.13
Preoperative variables only
Male sex 1.48 1.93
Age ,12 y 2.63 2.78
Preoperative LV function: moderate to severely reduced 2.27 2.44
Pulmonary valve stenosis: mild or greater 2.00 5.37
Previous surgical procedure 2.22
Prior cavopulmonary shunt 3.07
Mitral valve regurgitation requiring surgical intervention 11.37
TV, Tricuspid valve; LVAD, left ventricular assist device; RVAD, right ventricular assist device; ICU, intensive care unit; HCT, hematocrit; ECG, electrocardiog-
raphy; RV, right ventricular; LV, left ventricular; PA, pulmonary artery; MV, mitral valve; EP, electrophysiologic; HR, hazard ratio.CH
Dthan 12 years of age, those who had a TVrpl were statistically
more likely to have the following characteristics: younger
age at the time of diagnosis, more recent date of operation,
reduced LV systolic function, more anatomically severe
Ebstein anomaly, more likely to be ‘‘unrepairable’’ by means
of echocardiographic analysis, have hypoplastic or stenotic
pulmonary arteries, have an enlarged right ventricle postop-
eratively, and less likely to have a plication or resection of
an atrialized portion of the ventricle.
Predictive Value of Preoperative Echocardiography
The echocardiographer attempted to predict the likelihood of
successful surgical valve repair in 284 cases. The sensitivity
was 59%, the specificity was 92%, the positive predictive
value was 65%, and the negative predictive value was 90%.
Protective Effect of Pre-excitation
In several analyses the presence of ventricular pre-excita-
tion or its likely surrogates (ie, preoperative arrhythmia, ab-
lation of accessory pathways) was associated with
improved survival. The only differences between patients
with and without pre-excitation were surgeon (surrogate
for surgical division of bypass tract), degree of MV regur-
gitation, prior closure of an ASD or PFO, history of anThe Journal of Thoraarrhythmia, year of operation, and age at the time of the
operation. There did not appear to be a relationship between
the severity of the Ebstein anomaly and the presence of
pre-excitation.
Discussion
The management of Ebstein anomaly requires a choice be-
tween nonoperative treatment and operative interventions.
This choice may be difficult because of the very broad spec-
trum of severity of Ebstein anomaly. Patients with very
severe forms of Ebstein anomaly can die in utero or shortly
after birth, but patients with mild forms of the anomaly can
be completely asymptomatic for their entire life and never
need specific treatment. There are no randomized trials com-
paring the results of surgical treatment with those of nonsur-
gical treatment. Celermajer et al6 found that greater severity
of Ebstein anomaly, cardiothoracic ratio of greater than
60%, RVOT obstruction, and presentation as a fetus were
associated with poorer survival. Interestingly, ventricular
pre-excitation and era of diagnosis were not associated with
increased risk of death. Attie et al7 also reported that poorer
outcome was associated with more severe forms of Ebstein
anomaly, male sex, cyanosis, worse functional status, severe
TR, and early age at diagnosis in 72 unoperated adultcic and Cardiovascular Surgery c Volume 135, Number 5 1131
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Dpatients. Thus the indications for operation we used in the
current study seem reasonable.
Our study is consistent with the findings of previous stud-
ies6,7 because male sex, RVOT obstruction, cyanosis, and
more severe forms of the anomaly were associated with
poorer outcome. Cardiomegaly was associated with poorer
outcome in our study in a univariate, but not in a multivariate,
model.
Celermajer et al6 showed no effect of pre-excitation on
outcome, and in our study ventricular pre-excitation was as-
sociated with better outcome. Many patients in this study
were operated on before the era of transvenous catheter ab-
lation. We speculated that the improved survival occurred
because the primary indication for operation was for surgical
division of the bypass tract, and these patients might have
had less severe forms of Ebstein anomaly at the time they
had their operations.9,10 However, except for the fact that pa-
tients who had pre-excitation were younger than those with-
out pre-excitation, our data did not support this speculation.
It might also be that patients who have but are unknown to
have a bypass tract might die later because of a ventricular
Figure 4. A and B, Survival free from late reoperation on the tri-
cuspid valve (TV) for patients less than 12 or 12 or more years of
age. The 35 patients who had TV replacement and had prior TV
repair followed by TV replacement were removed from the TV
replacement group.1132 The Journal of Thoracic and Cardiovascular Surgery c Marrhythmia. Thus patients who have a bypass tract and re-
ceive proper treatment might have a survival advantage
when compared with patients who have not undergone
adequate treatment.
Echocardiographic Assessment of Valve Reparability
in Ebstein Anomaly
Favorable echocardiographic criteria for TVrpr include both
the valve leaflet location and morphology and the papillary
muscle location and attachments. Valves that have severe
leaflet displacement into the RV apex or those anteriorly
rotated into the RVOT are generally not suitable for the tra-
ditional monocusp repair. These forms of Ebstein anomaly
leave very little effective right ventricle below the point of co-
aptation. If the echocardiographer does not view TV tissue in
the apical 4-chamber view, the valve will typically need to be
replaced. However, it is possible that the apical 4-chamber
view can be angled anteriorly, so that some of the outflow
tract is in view. In this projection one might falsely believe
that the septal leaflet is present near the true TV inlet. The in-
ternal cardiac crux should be identified to avoid this pitfall.
Views from the parasternal short-axis projection at the base
of the heart can aid in identifying the proximity of TV tissue
in the RVOT to the pulmonary valve. If the anterior leaflet is
tethered at multiple sites (most importantly the tip), then the
surgeon might have difficulty mobilizing the leaflet, and
coaptation with the septum will be ineffective. The apical
4-chamber projection can be used to determine the tethering
sites of the anterior leaflet. Positioning of the papillary mus-
cles can be assessed from most imaging planes and is impor-
tant for assessment of leaflet mobility. Dense papillary
muscle attachments to the anterior leaflet can prohibit a tradi-
tional repair. Sacrificing these attachments might result in im-
portant residual TV regurgitation after repair.
Valves that have multiple leaflet fenestrations (hence mul-
tiple jets of TR) might be difficult to repair because of a defi-
ciency of useable tissue. Color Doppler assessment of TR can
be difficult because RV systolic pressure is usually normal in
these patients, and regurgitant jets can appear as very laminar
color flow. In addition, these jets can be oriented in directions
that are not usually expected. The severity of TR is frequently
underestimated by the inexperienced echocardiographer.
Principles of color Doppler scanning are based on jet velocity
and not on the quantity of regurgitation. This can have impor-
tant implications because surgical intervention might be
inappropriately deferred if the amount of TR is underesti-
mated. The preoperative echocardiographic assessment of
the patient with Ebstein anomaly requires meticulous use of
all imaging planes and experience gathered from evaluating
large numbers of these patients.
Caveats
In this study we hoped to identify the determinants of poor
outcome and the determinants of good outcome. Intuitively,ay 2008
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Dand based on prior small studies, one might suggest that RV
size and function, as well as LV systolic function and other
measures of severity of TV dysplasia, would correlate with
outcome. Because our study is retrospective, we had to use
echocardiographic data obtained over a 33-year period.
These data were not reported in a uniform fashion. Also,
over the study, measurement of RV size and function was
(and remains) imperfect by means of echocardiographic anal-
ysis. In addition, because of leftward displacement of the
ventricular septum, it is difficult to know the implications
of measured LV ejection fraction. Despite these caveats,
RV size and both RV and LV systolic function are important
determinants of outcome. Improved measurements of ven-
tricular size and function, such as could be obtained with
magnetic resonance imaging, might increase the usefulness
of ventricular size and function in predicting outcome.
Mortality
Previously, we reported early mortality of 6.3% for 189 pa-
tients who underwent TVrpr or TVrpl (these 189 patients
are an early part of the current cohort). In the current era
mortality ranges from 2.5% to 31%.2,5,8,11-21 In a collabora-
tive study of 150 patients, the early mortality was reported as
13%.8 In the current report the early mortality was 6% for all
539 patients, 5% for the 182 patients who had TVrpr, and 6%
for the 378 patients who had TVrpl. Considering only the op-
erations since 2001, perioperative mortality decreased to
2.7% (operations 5 110).
Total mortality in the current study (20 year; both early
and late) was 29% for all patients, 24% for patients who
had TVrpr, and 32% for patients who had TVrpl. To our
knowledge, there are no other studies of this magnitude and
length of follow-up with which to compare our results.
Reoperation
We presented risk of late reoperation in 2 formats: freedom
from late reoperation and survival free from late reoperation.
In both analyses, 10- and 20-year freedom from reoperation
was better in the valve repair than in the valve replacement
group. The highest rate of reoperation was in patients less
than 12 years of age who had valve replacement. These re-
sults, however, are not just a function of whether the valve
was replaced or repaired but, more importantly, on the sever-
ity of the disease that led to the decision to repair or replace
the valve. The decision to repair or replace the valve is guided
by whether the valve is amenable to repair with minimal re-
sidual valve regurgitation, as well as comorbid conditions,
which might sway the surgeon to do the quickest operation
with the shortest ischemic time. For example, a patient with
severely reduced RV systolic function, moderately reduced
LV systolic dysfunction, hypoplastic pulmonary arteries,
and secondary erythrocytosis might be better served by valve
replacement than by an attempted valve repair associated
with moderately-severe residual regurgitation.The Journal of ThoraValve Repair Versus Valve Replacement
An important question is whether it is better to repair or
replace the TV. Intuitively, one might suggest that the oper-
ation associated with lower mortality and lower reoperation
rate would be the preferable operation. However, if the goal
of the operation is to reduce or eliminate the volume overload
of the right atrium and ventricle, then the operation that is as-
sociated with a lesser degree of residual TR might be prefer-
able. In this study the 20-year survival for TVrpr was 76%,
and that for TVrpl was 67%. Survival free from reoperation
at 20 years for valve repair was 53% for patients operated
on at less than 12 years of age and 57% for patients operated
on at more than 12 years of age. Survival free from reopera-
tion at 20 years for valve replacement was 16% for patients
operated on at less then 12 years of age and 60% for patients
operated on at more than 12 years of age.
One must resist the temptation to conclude that valve re-
pair is inherently superior to valve replacement based on
these data. It is clear that those patients who had valve re-
placement had more severe disease than those who had valve
repair. In addition, significant residual TV regurgitation per-
sisted in 33% of patients who had valve repair but in only 1%
of patients who had valve replacement. This would favor
valve replacement. It also is important not to conclude that
one operation is superior to the other based on short-term out-
come because medium- to late-term failure of valve repair
clearly occurs.
For patients 12 years of age and older, we believe that the
valve should be repaired if there is not more than moderate
residual TR at the end of the operation. If there is greater
than moderate residual TR, we believe the valve should be
replaced because of the long-term effects of TR on RV func-
tion. For patients younger than 12 years of age, greater
degrees of TV regurgitation might be acceptable because of
the relatively greater need for reoperation for repeat valve
replacement in this age group.
Numerous techniques have been described for repair
of the TV since the first report of Hunter and Lilli-
hei.1,2,13,17,20-32 This is not surprising because no 2 hearts
with Ebstein anomaly have exactly the same anatomy. In ad-
dition, the enormous number of repair techniques is likely the
result of incomplete satisfaction with current repair methods
already described. Although many of the techniques avail-
able report good early results, very few document late out-
comes. Undoubtedly, the techniques for valve repair will
continue to evolve, and newer promising methods of repair
need to be evaluated to determine whether a greater percent-
age of valves can be repaired while maintaining good long-
term durability.16,33
Summary
We believe this is the largest surgical series of patients with
Ebstein anomaly. Because we incorporated greater than 125
potential independent variables and assessed numerouscic and Cardiovascular Surgery c Volume 135, Number 5 1133
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Ddependent outcomes, there are numerous variables that were
related to outcome both in a univariate fashion, multivariate
fashion, or both. All of these can be important when trying to
predict the early and late outcome of an operation. Table 7
provides a summary of the variables that were statistically
significantly associated with 1 or more of the dependent out-
come variables in a multivariate model.
In conclusion, it appears that male sex, RVOT obstruction
(including pulmonary stenosis and hypoplastic or stenotic
pulmonary arteries), MV regurgitation requiring surgical
intervention, cyanosis, and of the RV and/or LV systolic
dysfunction are among the more important preoperative
variables that are predictive of higher mortality. These vari-
ables should be helpful in stratifying patients’ potential oper-
ative risk.
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Discussion
Dr Vaughan A. Starnes (Los Angeles, Calif). I would like to con-
gratulate Dr Dearani on an excellent and clear presentation. Dr Dear-
ani and his colleagues have presented a comprehensive review of the
Mayo Clinic’s experience with surgical treatment of 539 patients
with Ebstein anomaly over a 34-year period of time. I believe this
represents the largest and most comprehensive review thus far.
The Mayo operation consisted of TVrpl in 61%, TVrpr in 34%, con-
comitant ASD closure in 84% and plication of the right ventricle in
35%, and ablation of the pathway in 13%. The early mortality was
excellent at a low value of 6%, and the overall survival of the entire
cohort treated at 10 and 20 years was 85% and 71%, respectively.
An extensive analysis of variables predicting early and late mortalityy 2008
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Dwere analyzed. As we have seen in the presentation, a multivariant
analysis was performed, and predictors of overall mortality were mi-
tral regurgitation, moderate-to-severe RV dysfunction, RVOT or
pulmonary artery reconstruction, and TVrpl.
This leads me to my first question, Joe, which is one of 3.
In your paper and presentation TVrpr is advocated and seems to
be related to better survival, and yet it seems you have replaced more
valves than you repaired, and this tendency seems to be increasing in
the more recent experience. Based on this large experience, what are
the determinants currently used to see whether the valve is repair-
able, and what degree of insufficiency would you accept?
Dr Dearani. Thank you for your remarks, Dr Starnes. We prefer
TVrpr when the valve is repairable. In recent years, there has been
a tendency for more replacement, which we believe is the result of
2 major reasons. First, in the adult population the durability of a tri-
cuspid bioprosthesis is excellent, and the freedom from reoperation
is actually much better with a bioprosthesis than with a fair repair.
The second reason is that recently there has been a greater percent-
age of patients who have already undergone a previous operation
elsewhere, and in our experience the chances to rerepair a valve in
that setting are rarely successful.
Dr Starnes. My second question—and I think I know your bias
but to clarify it—if the valve is to be replaced, which valve are we
going to use, a mechanical or a tissue valve?
Dr Dearani. Of approximately 350 TVrpls, about 300 were bio-
prosthetic, and 45 were mechanical. We prefer bioprostheses for 2
reasons: first, the durability is excellent, and second, our ability to
successfully treat atrial arrhythmias with the concomitant maze pro-
cedure has improved in recent years. Consequently, we are able to
optimize the ability to spare the patient from long-term warfarin an-
ticoagulation.
The patients we would consider for mechanical TVrpl would re-
ally be those who require anticoagulation for another reason, specif-
ically a left-sided mechanical prosthesis, which occurs very
infrequently. There are some important observations that we have
made with regard to mechanical TVrpl in Ebstein anomaly that
are worth mentioning. First, it is easy to insert a very large prosthesis
because the true tricuspid annulus is usually severely dilated. Cau-
tion should be exercised that the prosthesis is not oversized when
a mechanical valve is being used. In the presence of RV dysfunction,
which is always present in Ebstein anomaly, the discs might not
open and close normally. Thus the risk of thrombosis-related prob-
lems with a mechanical prosthesis is greater in this setting, and
therefore there is a need for even stronger anticoagulation. For all
of these reasons, we prefer a porcine bioprosthesis when valve re-
placement is required.
Dr Starnes. The last question, Joe, and maybe the most difficult
to answer is this: Given the variability of a clinical presentation of
Ebstein anomaly and your extensive experience, when should a pa-
tient undergo an operation?
Dr Dearani. The timing of the operation can be challenging for
some patients. In general, clinical deterioration and progressive
symptomatology with Ebstein anomaly occurs over a long period
of time, generally years. Consequently, it is uncommon to advise
an operation at the initial outpatient visit. When symptoms are ab-
sent, the decision to operate is usually based on serial changes
that occur on echocardiograms. We have learned from this study
that the presence of significant RV dysfunction is a powerful predic-The Journal of Thorator of outcome. With this in mind, an operation should be advised
before significant RV dysfunction, and I will say that that is not al-
ways easy to ascertain. Determination of RV function is challeng-
ing. We currently use both echocardiographic analysis and
magnetic resonance imaging to quantitate the function of the right
ventricle, and on many occasions we have found marked discrep-
ancies in the results between these 2 diagnostic modalities. We con-
tinue to learn from both echocardiography and magnetic resonance
imaging, but at the current time, there are limitations for both.
Other indications for surgical intervention include abnormal ex-
ercise tolerance, cyanosis, the presence or progression of arrhyth-
mias, and progressive increase in RV size. If echocardiography
suggests high probability of TVrpr, then we would advise an earlier
operation.
Dr Starnes. Again, I would like to congratulate the author on an
excellent presentation and the manuscript that was given to me in
advance, and I would like to thank the Association for the floor.
Dr Afksendiyos Kalangos (Geneva, Switzerland). How do you
evaluate RV function, by means of echocardiography or magnetic
resonance imaging, and what are the criteria for RV dysfunction
of more than moderate degree?
Dr Dearani. As I indicated earlier, echocardiography is very im-
perfect. In my experience echocardiography can tell you whether the
RV function is good or whether it is bad; everything in between is
very difficult to quantitate. Magnetic resonance imaging evaluation
appears to be more objective in terms of being able to provide an
ejection fraction. However, in a given patient there have been cir-
cumstances when the echocardiography suggested good RV func-
tion and the magnetic resonance imaging suggested poor RV
function and vice versa.
Therefore there is a lot to be learned in terms of quantitating RV
function in Ebstein anomaly. I do not have the answer. It is very
imperfect.
Dr Antonio Corno (Liverpool, United Kingdom). I enjoyed the
presentation. You presented a very small number of patients with
one and a half type of ventricular repair, and you say these have
been done in the last few years. Actually, you are limiting the indi-
cation to one and a half ventricular repair to the patient with severe
RV dysfunction. Do you consider that if you largely extend the in-
dication to one and a half ventricular repair, as done in other series,
you can dramatically reduce the number of TVrpls? If you use the
one and a half ventricular type of repair, you reduce one third of
the systemic venous return through the TV, and this is allowing
you to do a much better TVrpr in terms of reduced degree of residual
stenosis or regurgitation, and this would allow you to reduce the
need for TVrpl.
Dr Dearani. I agree. The point that is being made is whether the
addition of a bidirectional Glenn shunt improves the percentage of
successful repairs, and I think the answer is, in general, yes. With
that in mind, the bidirectional Glenn shunt is not a perfect solution
either. One issue with Ebstein anomaly that we are going to inves-
tigate in the future is exercise tolerance in patients who have had a bi-
ventricular repair with TVrpl versus those patients who have had
a bidirectional Glenn shunt (ie, a one and a half ventricle repair).
The one and a half ventricle repair, in my experience, helps re-
duce the early mortality in patients with profound RV dysfunction,
but the late results with the bidirectional Glenn shunt are unclear. In
addition, in this patient subgroup there is a high probability of latecic and Cardiovascular Surgery c Volume 135, Number 5 1135
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Darrhythmias, and the bidirectional Glenn shunt does affect the ability
to access the heart in the standard fashion for electrophysiologic
evaluation. Reducing the volume and size of the right ventricle
with a bidirectional Glenn shunt might enable a greater number of
successful tricuspid repairs by decreasing tension on suture lines
and allowing for a smaller annulus size without creating tricuspid
stenosis. At the current time, we apply the bidirectional Glenn shunt
selectively.
Dr Pedro Becker (Santiago, Chile). Do you have information
on whether the RV dysfunction gets better after surgical interven-
tion? Did you evaluate that and whether it is related to prognosis?
Also, what has been your incidence of heartbeat block in TVrpl?
DrDearani. In our experience the incidence of heart block is 2%
or less with TVrpl. We place the suture line cephalad to the true tri-
cuspid annulus and conduction tissue.1136 The Journal of Thoracic and Cardiovascular Surgery c MaInvestigation of preoperative and postoperative RV function is
another area of great interest. Most investigation is being done
with magnetic resonance imaging evaluation. Ebstein anomaly is
an RV myopathy, and all of the maneuvers that we do in the oper-
ating room do not take away the fact that a myopathy is still present.
We believe that plication or resection of the atrialized right ventricle
is reasonable and should be done at the discretion of the surgeon. We
believe that reducing the size of a markedly dilated right ventricle
might increase the efficiency of the right ventricle and perhaps indi-
rectly improve function. We know that the size of the right ventricle,
in general, gets smaller after you eliminate the regurgitant lesion. It
is not well documented at this time whether this results in improve-
ment in RV function. Magnetic resonance imaging examination
preoperatively and postoperatively should help delineate this in
the future.y 2008
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DAppendix E1. Independent variables of interest
Demographics and laboratory data
Age at operation
Age at diagnosis by history
Patient sex
Surgeon (1 and 2)
Year of operation





Preoperative right ventricular size
Preoperative right ventricular systolic function
Preoperative tricuspid valve regurgitation severity
Preoperative left ventricular systolic function
Anatomic severity of Ebstein anomaly
TV repairable: yes, no, equivocal
Mitral valve systolic regurgitation
Pulmonary valve stenosis
Architecture of pulmonary arteries: hypoplastic, stenotic, or
normal
Postoperative right ventricular size
Postoperative right ventricular systolic function
Postoperative tricuspid valve regurgitation severity
Postoperative left ventricular systolic function
Associated heart disease




Atrioventricular node re-entry tachycardia
Bilateral superior venae cavae
Patent ductus arteriosus
Partial atrioventricular septal defect
Coronary artery disease on angiography




Mitral valve regurgitation requiring surgical intervention
Subvalvular pulmonary stenosis/right ventricular outflow
tract obstruction
Pulmonary artery stenosis or hypoplasia
Pulmonary valve regurgitation
Miscellaneous associated cardiac defects not included in
any above
Previous cardiovascular procedure
Any prior cardiac procedure, including surgical procedures,
pacemakers, and catheter-based interventions
Prior closure of atrial septal defect
Prior tricuspid valve repair
Prior tricuspid valve replacement
Prior systemic-to-pulmonary artery shunt
Prior cavopulmonary shunt
Prior permanent pacemaker
Prior ablation of accessory pathway: catheter based and
surgical basedThe Journal of ThoraPrior closure of ventricular septal defect
Prior pulmonary valvotomy
Prior tricuspid valve replacement
Prior pulmonary artery banding
Prior coronary stenting or coronary artery bypass grafting
Prior repair of coarctation
Prior closure of patent ductus arteriosus
Prior enlargement of right ventricular outflow tract
Prior complete pericardiectomy
Prior left superior vena cava ligation
Surgical procedure
Closure of atrial septal defect
Right reduction atrioplasty




Ablation of accessory pathway(s)
Right-sided maze procedure
Closure of any shunt
Systemic-to-pulmonary shunt
Cavopulmonary shunt
Repair of pulmonary valve stenosis
Closure of ventricular septal defect
Ablation of atrioventricular node re-entrant tachycardia
Fontan procedure
Coronary stenting or coronary artery bypass grafting
Repair of coarctation
Repair of partial atrioventricular septal defect
Systemic-to-pulmonary artery shunt
Coronary artery bypass grafting
Repair of partial anomalous pulmonary veins
Permanent pacing wires
Miscellaneous arrhythmia procedure: ablation of right or left
isthmus or left-sided maze procedure




Enlargement of right ventricular outflow tract
Branch pulmonary artery enlargement
Electrophysiologic mapping
Closure of patent ductus arteriosus
Mechanical support and transplantation
Miscellaneous operation not listed above
Early nonfatal complications (,30 d)
Third-degree heart block, transient (,3 d)
Third-degree heart block, permanent
Ventricular arrhythmia: premature ventricular contractions,
ventricular tachycardia, or fibrillation
Wide complex tachycardia: ventricular tachycardia or
fibrillation
Junctional tachycardia
Atrial arrhythmia: atrial fibrillation, atrial flutter, premature
atrial contractions, supraventricular tachycardia
Miscellaneous arrhythmia not listed above
Myocardial infarction
Cerebrovascular accidentcic and Cardiovascular Surgery c Volume 135, Number 5 1136.e1
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DLow cardiac output state: inotropes .3 d
Intra-aortic balloon pump inserted in the intensive care unit
Respiratory insufficiency: ventilated .3 d
Renal insufficiency: .3 mg/dL
Dialysis
Gastrointestinal bleed
Deep sternal wound infection
Extracorporeal membrane oxygenation
Sepsis or endocarditis or pneumonia
Neurologic complication: seizures or transient ischemic
attack








Permanent pacemaker for third-degree heart block








Emergency opening of the chest in the intensive care unit
Miscellaneous early reoperation not listed above
Arrhythmia data
Past history of any arrhythmia (including palpitations and
other arrhythmias)
Past history of a specific arrhythmia (excluding palpitations)
Cardiac arrest before operation (before entering the
operating theater)
Accessory pathway on electrophysiologic study
Atrioventricular nodal re-entry tachycardia on
electrophysiologic study
Inducible ventricular tachycardia on electrophysiologic study
Inducible ventricular fibrillation on electrophysiologic study
Catheter ablation procedure on electrophysiologic study
Patients in sinus rhythm preoperatively on
electrocardiography
Patients with pre-excitation on preoperative
electrocardiography
Patients in sinus rhythm at dismissal on electrocardiography
QRS duration on dismissal or follow-up electrocardiographyay 2008
Brown et al Surgery for Congenital Heart DiseaseTABLE E1. Patient age at date of operation
All patients
(first operation at Mayo Clinic; n 5 539)
Tricuspid valve
repair group (n 5 182)
Tricuspid valve
replacement group (n 5 378)
Age at operation (y) N % N % N %
#10 156 29 39 21 112 30
11-20 115 21 51 28 68 18
.20 268 50 92 51 198 52The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 5 1136.e3
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DTABLE E2. Associated cardiac defects
Patients
Total (n 5 539) %
ASD or PFO 452 83.9
Ventricular septal defect 23 4.3
Pulmonary stenosis requiring surgical intervention 32 5.9
Subvalvular pulmonary stenosis/RVOT obstruction 9 1.7
Pulmonary artery stenosis or hypoplasia 8 1.5
Severe pulmonary regurgitation 4 0.7
Coronary artery disease by catheterization 9 1.7
Partial atrioventricular septal defect 8 1.5
Bilateral superior venae cavae 7 1.3
Patent ductus arteriosus 6 1.1
Absent coronary sinus 7 1.3
Mitral regurgitation (moderate to severe) 7 1.3
Pericarditis 5 0.9
Anomalous pulmonary venous connection 4 0.7
Hypertrophic obstructive cardiomyopathy 4 0.7
Miscellaneous cardiac defects 45 8.4
ASD, Atrial septal defect; PFO, patent foramen ovale; RVOT, right ventricular outflow tract.1136.e4 The Journal of Thoracic and Cardiovascular Surgery c May 2008
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Patients
Total (n 5 539) %




Inducible ventricular tachycardia or
fibrillation
18 3.3
Cardiac arrest before surgical
admission
15 2.8The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 5 1136.e5
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DTABLE E4. Early complications (patients who died within 30 days are excluded)
Patients
Total (n 5 506) %
Atrial arrhythmia: atrial fibrillation, atrial flutter, PACs, SVT 77 15.2
Ventricular arrhythmia: PVCs, Ventricular tachycardia, or
ventricular fibrillation
72 14.2
Wide complex tachycardia: ventricular tachycardia or
ventricular fibrillation only
42 8.3
Low cardiac output state 29 5.7
Respiratory insufficiency 28 5.5
Transient third-degree heart block 23 4.5
Junctional tachycardia 21 4.1
Sepsis or endocarditis or pneumonia 18 3.6
Renal insufficiency 12 2.4
Permanent third-degree heart block 11 2.2
Thrombus on tricuspid valve or in right atrium 9 1.8
Intra-aortic balloon pump 8 1.6
Dialysis 8 1.6
Deep sternal wound infection 6 1.2
Miscellaneous arrhythmias 5 1.0
Neurological complication: seizures, TIA 5 1.0
Hematologic complication 3 0.6
Myocardial infarction 2 0.4
Cerebrovascular accident 1 0.2
Gastrointestinal bleed 1 0.2
PACs, Premature atrial contractions; SVT, supraventricular tachycardia; TIA, transient ischemic attack.1136.e6 The Journal of Thoracic and Cardiovascular Surgery c May 2008
Brown et al Surgery for Congenital Heart DiseaseTABLE E5. Early cardiac reoperations (within 30 days)
Patients
Total (n 5 539) %
Bleeding 16 3.0
Secondary sternal closure 16 3.0
Miscellaneous other early reoperations 13 2.4
Permanent pacemaker for third-degree HB 12 2.2
Emergency opening of the chest in the intensive care unit 11 2.0
Tamponade 10 1.9
Permanent pacemaker for miscellaneous reason 9 1.7
LVAD, RVAD, or mechanical support in perioperative period 6 1.1
Tricuspid valve reoperation 4 0.7
Wound debridement 4 0.7
Closure of shunt 3 0.6
Pericardiectomy 3 0.6
Creation of shunt 2 0.4
HB, Heart block; LVAD, left ventricular assist device; RVAD, right ventricular assist device.The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 5 1136.e7
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